Skip to content
MarketScale
‹ Back to IndustriesSciences

Aerobic Exercise Linked to Brain Cell Health

Recent studies at the University of Ottawa and The University of British Columbia have discovered a link between brain health and aerobic exercise. While it’s no secret that exercise is good for the physical body, aerobic exercise can stimulate memory, reduce stress and anxiety and improve problem-solving functions, especially in older adults. This is well…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Featured ·
Share
Aerobic Exercise Linked to Brain Cell Health

Key takeaways

01

Recent studies at the University of Ottawa and The University of British Columbia have discovered a link between brain health and aerobic exercise.

02

While it’s no secret that exercise is good for the physical body, aerobic exercise can stimulate memory, reduce stress and anxiety and improve problem-solving functions, especially in older adults.

Recent studies at the University of Ottawa and The University of British Columbia have discovered a link between brain health and aerobic exercise. While it’s no secret that exercise is good for the physical body, aerobic exercise can stimulate memory, reduce stress and anxiety and improve problem-solving functions, especially in older adults.

This is well documented in runners. Those who run for extended amounts of time get what is known in the field as “runner’s high” in which the brain produces a chemical called VGF- a natural opioid that stimulates a sense of euphoria. This correlates with lower levels of stress after a run, and lower memory of stressful situations after a run is completed.

Eli Puterman, Ph.D., the lead researcher and a professor of kinesiology at the University of British Columbia chimes in. “We are constantly rewriting our memories, so of course, if exercise makes me happy or calm more often, I might interpret the stressor as less impactful as it’s happening but I might also recall it later as less stressful.”[1]

While there is no one exercise that is best for the brain, exercise at any stage has proven to slow the signs of brain-related illnesses, including dementia, and other health risks like hypertension and diabetes.

[1]

https://www.runnersworld.com/psychology/why-you-should-run-stressful-times

About the author

F
Featured

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

F
Featured

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512